According to the FDA, 21 vaccinated and 17 unvaccinated people died in Pfizer's approval study. Nevertheless, Comirnaty was provisionally approved as "life-saving." Now it turns out that there were twice as many sudden and unexpected deaths in the vaccinated group as in the placebo group. (translated)
Το 21 πάει να γίνει νούμερο σταθμός για εμένα ☘️💚 #paofc https://t.co/FDAJiz9s1r #προσωπικηαναπτυξη #επιτυχία #PAO
Heaven on earth that Marxism-Leninism promised to the proletariat has not materialized. The regime aimed to ensure the growth and strengthening of the Russian state. This is written by an author whom Putin condemned as a terrorist and extremist in absentia (he lives in London) and banned the book. (translated)
Kurz nach Klageandrohung beginnt das PEI, bei der amerikanischen Zulassungsbehörde FDA anzufragen, was geschwärzt werden müsste. Dieses übliche Drittbeteiligungsverfahren hätte das PEI eigentlich schon im Januar 2026 beginnen müssen. Scheinbar wird das Informationsfreiheitsgesetz im PEI nur ernst genommen, wenn geklagt wird. Die FDA und andere Beteiligte haben nun einen Monat Zeit, ihre Schwärzungswünsche einzubringen. Danach muss das PEI den Mailverkehr zwischen Cichutek und Keller-Stanislawski offen legen. #Transparenz #Informationfreiheit #PEI
The American Food and Drug Administration (FDA) accelerated the introduction of the drug Rasonque (daraksonrasib) to the market for patients with advanced pancreatic cancer, which extended the median survival to 13.2 months and reduced the risk of death by about 60%. (translated)
Daraxonrasib, a new RAS inhibitor, has been approved by the FDA in the USA, which may significantly extend the life of patients with metastatic pancreatic cancer, raising the median survival to 13.2 months compared to the previous 6.7 months offered by standard chemotherapy. (translated)
🧓🏼 El curioso caso de Fernando Alonso 🚥 Con 45 años, fue el piloto con mejor tiempo de reacción en la salida de Zandvoort 🐐 📊 @FDataAnalysis https://t.co/5wzrNFOSjo #FernandoAlonso #F1 #Motorsport
The American FDA has approved a drug called darasozumab, which effectively extends the survival time of pancreatic cancer patients, and as a result, the audience applauded the research results at an oncology conference. (translated)
The US Food and Drug Administration (FDA) has approved the new medication Rasonque for the treatment of pancreatic cancer, which doubles the survival time for patients with advanced disease and provides hope to many sick individuals, despite the high costs. (translated)
In the United States, the FDA has approved a new treatment called daraxonrasib for metastatic pancreatic cancer, which increases the median survival of patients from 6.7 months to 13.7 months, bringing hope even to advanced cases like that of former senator Ben Sasse. (translated)
The FDA has approved the new Rasonque pill for pancreatic cancer, which doubles the life expectancy of patients by blocking the mutated KRAS gene, offering a new hope for one of the deadliest forms of cancer. (translated)
The US drug agency FDA has approved the drug Rasonque for the treatment of pancreatic cancer, which has shown in clinical trials that it can double the lifespan of certain patients, although it does not provide a cure. (translated)
The U.S. Food and Drug Administration (FDA) has approved a new revolutionary drug Rasonque for the treatment of metastatic pancreatic cancer, which doubles the survival rate of patients and becomes available for $39,800 per month. (translated)
The American Food and Drug Administration (FDA) has approved the revolutionary drug Rasonque for advanced pancreatic cancer, which doubles the survival rate of patients according to clinical trials, providing new hope for those afflicted by this deadly cancer. (translated)
The American Food and Drug Administration (FDA) has approved the revolutionary drug Rasonque for the treatment of metastatic pancreatic cancer, which doubles the survival rate of patients and causes fewer side effects than traditional chemotherapies, and is now available in the U.S. for a price of $39,800 per month. (translated)
The FDA has approved the revolutionary drug Rasonque for metastatic pancreatic cancer, which shows improved patient survival and is available at a cost of $39,800 per month, with co-funding options for insured patients. (translated)
